Primary radical therapy selection in high-risk non-metastatic prostate cancer

Clinical Oncology

Volumn 27, Issue 3, 2015, Pages 136-144

  Gnanapragasam, V J ^a,b   Payne, H ^c   Syndikus, I ^d   Kynaston, H ^e   Johnstone, T ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^e UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Decision algorithm; High risk; Prostate cancer; Radical prostatectomy; Radical radiotherapy; Rational therapy selection

Indexed keywords

ARTICLE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER THERAPY; COMORBIDITY; DISEASE COURSE; HIGH RISK PATIENT; HUMAN; LIFE EXPECTANCY; MALE; MEDICAL INFORMATION; MORBIDITY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADICAL THERAPY; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; ADJUVANT THERAPY; PROSTATIC NEOPLASMS;

DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 84922067181     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.11.004     Document Type: Article

References (81)

1. Albertsen P.C., Hanley J.A., Penson D.F., Barrows G., Fine J. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. JUrol 2005, 177(3):932-936.
2. Rider J.R., Sandin F., Andrén O., Wiklund P., Hugosson J., Stattin P. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol 2013, 63(1):88-96.
3. Petrelli F., Vavassori I., Coinu A., Borgonovo K., Sarti E., Barni S. Radical prostatectomy or radiotherapy in high-risk prostate cancer: a systematic review and metaanalysis. Clin Genitourin Cancer 2014, 12(4):215-224.
4. Heidenreich A., Bellmunt J., Bolla M., et al. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011, 59(1):61-71.
5. Thompson I., Thrasher J.B., Aus G., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. JUrol 2007, 177(6):2106-2131.
6. Peschel R.E., Colberg J.W. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 2003, 4(4):233-241.
7. Akre O. Surgery versus radiotherapy for locally advanced prostate cancer (SPCG-15) 2014 March 31, ClinicalTrials.gov, National Library of Medicine (US), Identifier: NCT02102477.
8. Sooriakumaran P., Nyberg T., Akre O., et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. Br Med J 2014, 348(1502):1-13.
9. Boorjian S.A., Karnes R.J., Viterbo R., et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 2011, 117(13):2883-2891.
10. Abdollah F., Sun M., Thuret R., et al. Acompeting-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011, 59(1):88-95.
11. Kachroo N., Gnanapragasam V. The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review. JCancer Res Clin Oncol 2013, 139(1):1-24.
12. Gnanapragasam V.J. Molecular markers to guide primary radical treatment selection in localised prostate cancer. Expert Rev Mol Diag 2014, 14(7):871-881.
13. Gnanapragasam V.J., Persad R., Payne H.A. Radiotherapy and surgery for high-risk localised prostate cancer: a UK questionnaire survey of urologists and clinical oncologists. BJU Int 2012, 110(5):608-612.
14. NICE Prostate cancer: diagnosis and treatment 2014, NICE guidelines [CG175].
15. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. JClin Oncol 1999, 17(1):168.
16. Rodrigues W.P., Pickles T., Crook J., Brundage M., Souhami L., Lukka H. Pre-treatment risk stratification of prostate cancer patients: a critical review. Can Urol Assoc J 2012, 6(2):121-127.
17. Meng M.V., Elkin E.P., Latini D.M., DuChane J., Carroll P.R. Treatments of patients with high risk localised prostate cancer: results from Cancer of the Prostate Strategic Urological Research Endeavour (CaPSURE). JUrol 2005, 173(5):1557-1561.
18. Serag H., Banerjee S., Saeb-Parsy K., et al. Risk profiles of prostate cancers identified from UK primary care using national referral guidelines. Br J Cancer 2012, 106(3):436-439.
19. Greenberg D.C., Wright K.A., Lophathanon A., Muir K.R., Gnanapragasam V.J. Changing presentation of prostate cancer in a UK population - 10 year trends in prostate cancer risk profiles in the East of England. Br J Cancer 2013, 109(8):2115-2120.
20. Parker C.C., Norman A.R., Huddart R.A., Horwich A., Dearnaley D.P. Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer. Br J Cancer 2002, 86(5):686-691.
21. Sharma N.L., Papadopoulos A., Lee D., et al. First 500 cases of robotic-assisted laparoscopic radical prostatectomy from a single UK centre: learning curves of two surgeons. BJU Int 2011, 108(5):739-747.
22. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005, 294(4):433-439.
23. Uchio E.M., Aslan M., Wells C.K., Calderone J., Concato J. Impact of biochemical recurrence in prostate cancer among us veterans. Arch Intern Med 2010, 170(15):1390-1395.
24. Hsu C.-Y., Joniau S., Oyen R., Roskams T., Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 2007, 51(1):121-129.
25. Spahn M., Joniau S., Gontero P., et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 2010, 58(1):1-7.
26. D'Amico A.V., Schultz D., Silver B., et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2001, 49(3):679-684.
27. Widmark A., Klepp O., Solberg A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009, 373(9660):301-308.
28. Warde P., Mason M., Ding K., et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011, 378(9809):2104-2111.
29. Gnanapragasam V.J., Mason M.D., Shaw G.L., Neal D.E. The role of surgery in high-risk localised prostate cancer. BJU Int 2012, 109(5):648-658.
30. Guttilla A., Bortolus R., Giannarini G., et al. Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial. Radiat Oncol 2014, 9(1):24.
31. Tewari A., Divine G., Chang P., et al. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy - a propensity scoring approach. JUrol 2007, 177(3):911-915.
32. Zelefsky M.J., Eastham J.A., Cronin A.M., et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. JClin Oncol 2010, 28(9):1508-1513.
33. Hoffman R.M., Koyama T., Fan K.-H., et al. Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. JNatl Cancer Inst 2013, 105(10):711-718.
34. Winkelmayer W.C., Kurth T. Propensity scores: help or hype?. Nephrol Dial Transplant 2004, 19(7):1671-1673.
35. Månsson R., Joffe M.M., Sun W., Hennessy S. On the estimation and use of propensity scores in case-control and case-cohort studies. Am J Epidemiol 2007, 166(3):332-339.
36. Resnick M.J., Koyama T., Fan K.-H., et al. Long-term functional outcomes after treatment for localized prostate cancer. NEngl J Med 2013, 368(5):436-445.
37. Abdollah F., Suardi N., Cozzarini C., et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 2013, 63(6):998-1008.
38. Bolla M., van Poppel H., Tombal B., et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012, 380(9858):2018-2027.
39. Lawrence E.M., Gnanapragasam V.J., Priest A.N., Sala E. The emerging role of diffusion-weighted MRI in prostate cancer management. Nat Rev Urol 2012, 9(2):94-101.
40. Lawrence E.M., Gallagher F.A., Barrett T., Warren A.Y., Priest A.N., Goldman D., Sala E., Gnanapragasam V.J. Preoperative 3-T diffusion-weighted MRI for the qualitative and quantitative assessment of extracapsular extension in patients with intermediate- or high-risk prostate cancer. AJR Am J Roentgenol 2014 Sep, 203(3):W280-6.
41. Nelson A.W., Harvey R.C., Parker R.A., Kastner C., Doble A., Gnanapragasam V.J. Repeat prostate biopsy strategies after initial negative biopsy: meta-regression comparing cancer detection of transperineal, transrectal saturation and MRI guided biopsy. PLoS ONE 2013, 8(2):e57480.
42. Mitchell C.R., Boorjian S.A., Umbreit E.C., Rangel L.J., Carlson R.E., Karnes R.J. 20-year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int 2012, 110(11):1709-1713.
43. Ward J.F., Slezak J.M., Blute M.L., Bergstralh E.J., Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005, 95(6):751-756.
44. Abdollah F., Schmitges J., Sun M., et al. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol 2012, 19(9):836-844.
45. Sundi D., Wang V.M., Pierorazio P.M., et al. Very-high-risk localized prostate cancer: definition and outcomes. Prostate Cancer Prostatic Dis 2014, 17(1):57-63.
46. Tsai H.K., Chen M.-H., McLeod D.G., Carroll P.R., Richie J.P., D'Amico A.V. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer 2006, 107(11):2597-2603.
47. Briganti A., Spahn M., Joniau S., et al. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol 2013, 63(4):693-701.
48. Rapiti E., Fioretta G., Verkooijen H.M., et al. Increased risk of colon cancer after external radiation therapy for prostate cancer. Int J Cancer 2008, 123(5):1141-1145.
49. Daskivich T.J., Fan K.-H., Koyama T., et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med 2013, 158(10):709-717.
50. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. Anew method of classifying prognostic comorbidity in longitudinal studies: development and validation. JChronic Dis 1987, 40(5):373-383.
51. Fowler J.E., Terrell F.L., Renfroe L.D. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. JUrol 1996, 156(5):1714-1718.
52. Tsivian A.M., Polascik T.J. Evolution of the concept of focal therapy for prostate cancer. Oncology 2013, 27(1):64-68.
53. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61(5):1285-1290.
54. D'Amico A.V., Renshaw A.A., Loffredo B., Chen M.-H. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 2007, 110(8):1723-1728.
55. Tsai H.K., D'Amico A.V., Sadetsky N., Chen M.-H., Carroll P.R. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. JNatl Cancer Inst 2007, 99(20):1516-1524.
56. Budäus L., Bolla M., Bossi A., et al. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol 2012, 61(1):112-127.
57. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. NEngl J Med 2008, 358(12):1250-1261.
58. Ferrer M., Suárez J.F., Guedea F., et al. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72(2):421-432.
59. Katz A., Santoro M., Diblasio F., Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol 2013, 8(1):118.
60. Van Tol-Geerdink J.J., Leer J.W.H., van Oort I.M., et al. Quality of life after prostate cancer treatments in patients comparable at baseline. Br J Cancer 2013, 108(9):1784-1789.
61. Sveistrup J., Rosenschold P., Deasy J., et al. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol 2014, 9(1):44.
62. Lau W.K., Bergstralh E.J., Blute M.L., Slezak J.M., Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. JUrol 2002, 167(1):117-122.
63. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. NEngl J Med 1999, 341(24):1781-1788.
64. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. NEngl J Med 1997, 337(5):295-300.
65. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTCstudy): a phase III randomised trial. Lancet 2002, 360(9327):103-108.
66. Parekh A., Graham P.L., Nguyen P.L. Cancer control and complications of salvage local therapy after failure of radiotherapy for prostate cancer: a systematic review. Semin Radiat Oncol 2013, 23(3):222-234.
67. Pisters L.L., Leibovici D., Blute M., et al. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. JUrol 2009, 182(2):517-527.
68. Kimura M., Mouraviev V., Tsivian M., Mayes J.M., Satoh T., Polascik T.J. Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int 2010, 105(2):191-201.
69. Chin P.S., Mouraviev V., Touma N., Moore K., Downey D.B. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. JUrol 2001, 165(6):1937-1941.
70. Marcus C.D., Jani A.B., Dobbs R.W., Schuster D.M., Carthon B.C., Rossi P.J. Salvage therapy for locally recurrent prostate cancer after radiation. Can J Urol 2012, 19(6):6534-6541.
71. Chalasani V., Martinez C.H., Lim D., Chin J. Salvage HIFU for recurrent prostate cancer after radiotherapy. Prostate Cancer Prostatic Dis 2008, 12(2):124-129.
72. Chade D.C., Shariat S.F., Cronin A.M., et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol 2011, 60(2):205-210.
73. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005, 366(9485):572-578.
74. Wiegel B.D., Steiner U., Siegmann A., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. JClin Oncol 2009, 20(27):2924-3011.
75. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. JUrol 2009, 181(3):956-962.
76. Council MR Radiation therapy and androgen deprivation therapy in treating patients who have Undergone surgery for prostate Cancer (RADICALS) 2007 October 5, ClinicalTrials.gov, National Library of Medicine (US), Identifier: NCT00541047.
77. Cooperberg M.R., Pasta D.J., Elkin E.P., et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment Score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. JUrol 2005, 173(6):1938-1942.
78. Mohler B.R., Boston B., Busby J.E., et al. NCCN clinical practice guidelines in oncology: prostate cancer. JNatl Compr Canc Netw 2010, 8:162-200.
79. Burnet N.G., Barnett G.C., Elliott R.M., et al. RAPPER Investigators. RAPPER: the radiogenomics of radiation toxicity. Clin Oncol (R Coll Radiol) 2013, 25(7):431-434.
80. Aggarwal A., Cathcart P., Payne H., et al. The National Prostate Cancer Audit - introducing a new generation of cancer audit. Clin Oncol (R Coll Radiol) 2014, 26(2):90-93.
81. Lane J.A., Donovan J.L., Davis M., et al. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol 2014, 15(10):1109-1118. ProtecT study group.